139 related articles for article (PubMed ID: 29271963)
1. [Bifunctional Toxin DARP-LoPE Based on the HER2-Specific Innovative Module of a Non-Immunoglobulin Scaffold as a Promising Agent for Theranostics].
Proshkina GM; Kiseleva DV; Shilova ON; Ryabova AV; Shramova EI; Stremovskiy OA; Deyev SM
Mol Biol (Mosk); 2017; 51(6):997-1007. PubMed ID: 29271963
[TBL] [Abstract][Full Text] [Related]
2. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
Zielinski R; Lyakhov I; Jacobs A; Chertov O; Kramer-Marek G; Francella N; Stephen A; Fisher R; Blumenthal R; Capala J
J Immunother; 2009 Oct; 32(8):817-25. PubMed ID: 19752752
[TBL] [Abstract][Full Text] [Related]
3. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.
Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S
J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808
[TBL] [Abstract][Full Text] [Related]
4. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
[TBL] [Abstract][Full Text] [Related]
5. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
[TBL] [Abstract][Full Text] [Related]
6. Antibody internalization studied using a novel IgG binding toxin fusion.
Mazor Y; Barnea I; Keydar I; Benhar I
J Immunol Methods; 2007 Apr; 321(1-2):41-59. PubMed ID: 17336321
[TBL] [Abstract][Full Text] [Related]
7. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.
Sokolova EA; Zdobnova TA; Stremovskiy OA; Balalaeva IV; Deyev SM
Biochemistry (Mosc); 2014 Dec; 79(12):1376-81. PubMed ID: 25716732
[TBL] [Abstract][Full Text] [Related]
8. Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions.
Bachran C; Morley T; Abdelazim S; Fattah RJ; Liu S; Leppla SH
mBio; 2013 Apr; 4(3):e00201-13. PubMed ID: 23631917
[TBL] [Abstract][Full Text] [Related]
9. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues.
Schweizer A; Wöhner M; Prescher H; Brossmer R; Nitschke L
Eur J Immunol; 2012 Oct; 42(10):2792-802. PubMed ID: 22777817
[TBL] [Abstract][Full Text] [Related]
10. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
Onda M; Beers R; Xiang L; Lee B; Weldon JE; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5742-7. PubMed ID: 21436054
[TBL] [Abstract][Full Text] [Related]
11. Immunotoxin-mediated targeting of claudin-4 inhibits the proliferation of cancer cells.
Hashimi SM; Yu S; Alqurashi N; Ipe DS; Wei MQ
Int J Oncol; 2013 Jun; 42(6):1911-8. PubMed ID: 23563899
[TBL] [Abstract][Full Text] [Related]
12. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.
Onda M; Beers R; Xiang L; Nagata S; Wang QC; Pastan I
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11311-6. PubMed ID: 18678888
[TBL] [Abstract][Full Text] [Related]
13. Expression and purification of recombinant immunotoxin--a fusion protein stabilizes a single-chain Fv (scFv) in denaturing condition.
Kim SH
Protein Expr Purif; 2003 Jan; 27(1):85-9. PubMed ID: 12509988
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
15. A dominant-negative approach that prevents diphthamide formation confers resistance to Pseudomonas exotoxin A and diphtheria toxin.
Roy V; Ghani K; Caruso M
PLoS One; 2010 Dec; 5(12):e15753. PubMed ID: 21203470
[TBL] [Abstract][Full Text] [Related]
16. Engineering of bacterial exotoxins for highly efficient and receptor-specific intracellular delivery of diverse cargos.
Ryou JH; Sohn YK; Hwang DE; Park WY; Kim N; Heo WD; Kim MY; Kim HS
Biotechnol Bioeng; 2016 Aug; 113(8):1639-46. PubMed ID: 26773973
[TBL] [Abstract][Full Text] [Related]
17. Turn a diarrhoea toxin into a receptor-mediated therapy for a plethora of CLDN-4-overexpressing cancers.
Yao Q; Cao S; Li C; Mengesha A; Low P; Kong B; Dai S; Wei M
Biochem Biophys Res Commun; 2010 Jul; 398(3):413-9. PubMed ID: 20599713
[TBL] [Abstract][Full Text] [Related]
18. [Soluble expression of recombinant immunotoxin against human bladder carcinoma and its anti-tumor activity].
Chao K; He D; Yang H; Zhang Z; Lin Q; Guo AG; Huang HL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Sep; 20(5):568-71. PubMed ID: 15367349
[TBL] [Abstract][Full Text] [Related]
19. EGFR-targeted Chimeras of Pseudomonas ToxA released into the extracellular milieu by attenuated Salmonella selectively kill tumor cells.
Quintero D; Carrafa J; Vincent L; Bermudes D
Biotechnol Bioeng; 2016 Dec; 113(12):2698-2711. PubMed ID: 27260220
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
